Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Jane A. Reese"'
Autor:
Kim Anthony-Gonda, Alex Ray, Hang Su, Yuge Wang, Ying Xiong, Danica Lee, Ariele Block, Vanessa Chilunda, Jessica Weiselberg, Lily Zemelko, Yen Y. Wang, Sarah Kleinsorge-Block, Jane S. Reese, Marcos de Lima, Christina Ochsenbauer, John C. Kappes, Dimiter S. Dimitrov, Rimas Orentas, Steven G. Deeks, Rachel L. Rutishauser, Joan W. Berman, Harris Goldstein, Boro Dropulić
Publikováno v:
JCI Insight, Vol 7, Iss 21 (2022)
HIV-specific chimeric antigen receptor–T cell (CAR T cell) therapies are candidates to functionally cure HIV infection in people with HIV (PWH) by eliminating reactivated HIV-infected cells derived from latently infected cells within the HIV reserv
Externí odkaz:
https://doaj.org/article/07c21215b58f4bf69b7d186bb38fd62e
Autor:
Zachary Jackson, Anne Roe, Ashish Arunkumar Sharma, Filipa Blasco Tavares Pereira Lopes, Aarthi Talla, Sarah Kleinsorge-Block, Kayla Zamborsky, Jennifer Schiavone, Shivaprasad Manjappa, Robert Schauner, Grace Lee, Ruifu Liu, Paolo F. Caimi, Ying Xiong, Winfried Krueger, Andrew Worden, Mike Kadan, Dina Schneider, Rimas Orentas, Boro Dropulic, Rafick-Pierre Sekaly, Marcos de Lima, David N. Wald, Jane S. Reese
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Chimeric antigen receptor T cells (CAR-T cell) targeting CD19 are effective against several subtypes of CD19-expressing hematologic malignancies. Centralized manufacturing has allowed rapid expansion of this cellular therapy, but it may be associated
Externí odkaz:
https://doaj.org/article/8d0bad17627d4c10b8f6a1d433064624
Autor:
Zachary Jackson, Changjin Hong, Robert Schauner, Boro Dropulic, Paolo F. Caimi, Marcos de Lima, Maria Florencia Giraudo, Kalpana Gupta, Jane S. Reese, Tae Hyun Hwang, David N. Wald
Publikováno v:
Cancer Discov
Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Nonetheless, many patients receiving CD19 CAR-T cells fail to respond for unknown r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462e143b474f5e65333ae5432a3359a3
https://doi.org/10.1158/2159-8290.cd-21-1586
https://doi.org/10.1158/2159-8290.cd-21-1586
Autor:
David N. Wald, Tae Hyun Hwang, Jane S. Reese, Kalpana Gupta, Maria Florencia Giraudo, Marcos de Lima, Paolo F. Caimi, Boro Dropulic, Robert Schauner, Changjin Hong, Zachary Jackson
Supplementary Data from Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cd32d768f92a81d636f756943e38081
https://doi.org/10.1158/2159-8290.22541285
https://doi.org/10.1158/2159-8290.22541285
Autor:
David N. Wald, Tae Hyun Hwang, Jane S. Reese, Kalpana Gupta, Maria Florencia Giraudo, Marcos de Lima, Paolo F. Caimi, Boro Dropulic, Robert Schauner, Changjin Hong, Zachary Jackson
Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Nonetheless, many patients receiving CD19 CAR-T cells fail to respond for unknown r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46740b6ff450ce3136d10649161c8e01
https://doi.org/10.1158/2159-8290.c.6549602
https://doi.org/10.1158/2159-8290.c.6549602
Autor:
Ehsan Malek, Merle Kolk, R. M. Fox, James J. Driscoll, Paolo Caimi, Shivaprasad Manjappa, Amin Firoozamand, Marcos de Lima, Jane S. Reese, Hannah Schmikla, Savannah Nall
Publikováno v:
Blood. 136:35-37
Background High dose chemotherapy followed by autologous stem cell transplantation (ASCT) plays an important role in the treatment of transplant-eligible multiple myeloma (MM) patients and yields deep responses, prolongs progression-free survival (PF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::116e6d64d31ee851aea6f6cbca6aae6d
https://doi.org/10.1182/blood-2020-142115
https://doi.org/10.1182/blood-2020-142115
Autor:
David J. Chung, Nina Shah, Dina Stroopinsky, Juan (Maggie) Wu, Lina Bisharat, Natalie S. Callander, Brent Logan, Kenneth C. Anderson, Binod Dhakal, Steven M. Devine, Yvonne Efebera, Nancy Geller, Peiman Hematti, Leona A. Holmberg, Alan Howard, Bryon D Johnson, Hillard M. Lazarus, Ehsan Malek, Philip L. McCarthy, David H. McKenna, Adam Mendizabal, Nikhil C. Munshi, Lynn C. O’Donnell, Aaron P. Rapoport, Ajay Nooka, Jane S Reese, Robert J. Soiffer, Lynne Uhl, Giulia Cheloni, Dimitra Karagkouni, Ioannis Vlachos, Jim Young, Jacalyn Rosenblatt, Edmund K. Waller, Marcelo C Pasquini, David E. Avigan
Publikováno v:
Transplantation and Cellular Therapy. 28:S223-S224
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18cf8733a3a3a6079a37605e396662b5
https://doi.org/10.1016/s2666-6367(22)00443-2
https://doi.org/10.1016/s2666-6367(22)00443-2
Autor:
Zachary Jackson, Boro Dropulic, Jane S. Reese, Tae Hyun Hwang, Robert Schauner, M. de Lima, Paolo Caimi, David N. Wald, Kalpana Gupta, Changjin Hong
Chimeric antigen receptor T cell (CAR-T cell) therapy is known to produce durable remissions in the treatment of CD19+relapsed/refractory B cell malignancies. Nonetheless, a significant portion of patients receiving the therapy experience poor outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18e384040b735fca21763b8368472da2
https://doi.org/10.1101/2021.04.26.441326
https://doi.org/10.1101/2021.04.26.441326
Autor:
Andrew E Sloan, Jane S. Reese, Stanton L. Gerson, Hillard M. Lazarus, Hua Fung, Christopher Murphy, Lisa Rgers, Boro Dropulic
Publikováno v:
Neuro Oncol
INTRODUCTION GBM has median survival of 12 months despite current SOC therapy. The most important mechanism of TMZ resistance is the O6-methylguanine-DNA methyltransferase (MGMT) gene. The MGMT inhibitor O6-benzylguanine (BG) demonstrated efficacy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7856d747d692ac05bd1d305de5e1fcb1
https://europepmc.org/articles/PMC7651599/
https://europepmc.org/articles/PMC7651599/
Autor:
Leona Holmberg, Ajay K. Nooka, David Avigan, Robert J. Soiffer, Nancy L. Geller, Hillard M. Lazarus, Lynne Uhl, Kenneth C. Anderson, Jane S. Reese, Jacalyn Rosenblatt, Nina Shah, Steven M. Devine, David J. Chung, Bryon D. Johnson, Juan Wu, Dimitra Karagkouni, David H. McKenna, Ioannis S. Vlachos, Thinle Chodon, Giulia Cheloni, Natalie S. Callander, Brent R. Logan, Lina Bisharat, Alan Howard, Ehsan Malek, Nikhil C. Munshi, James W. Young, Yvonne A. Efebera, Aaron P. Rapoport, Meera Mohan, Marcelo C. Pasquini, Dina Stroopinsky, Lynn O'Donnell, Edmund K. Waller, Philip L. McCarthy, Peiman Hematti, Adam Mendizabal
Publikováno v:
Blood. 138:899-899
In a prior phase 2 study, personalized cancer vaccination with autologous dendritic cells (DCs) fused with primary MM tumor cells (DC/MM fusions) induced the expansion of circulating MM-reactive lymphocytes and was associated with conversion to compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a5a5e2e3aa175a59881d96622e17007
https://doi.org/10.1182/blood-2021-149659
https://doi.org/10.1182/blood-2021-149659